N@N

Colin Bristow Maintained (SRPT) at Strong Buy with Increased Target to $167 on, Mar 1st, 2024

Colin Bristow of UBS, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $164 to $167 on, Mar 1st, 2024.

Colin has made no other calls on SRPT in the last 4 months.

There are 10 other peers that have a rating on SRPT. Out of the 10 peers that are also analyzing SRPT, 2 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Kristen Kluska of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $128 on, Thursday, February 29th, 2024
• Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Hold with Increased Target to $138 on, Tuesday, February 20th, 2024

These are the ratings of the 8 analyists that currently disagree with Colin

---

• Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $157 on, Thursday, February 29th, 2024
• David Hoang of "Citigroup" Maintained at Strong Buy with Increased Target to $172 on, Thursday, February 29th, 2024
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $185 on, Thursday, February 29th, 2024
• Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Thursday, February 29th, 2024
• Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, February 20th, 2024
• Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $145 on, Wednesday, February 14th, 2024
• Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
• Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023

Contributing Sources

---